BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 26005879)

  • 1. Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy.
    Doria A; Iaccarino L; La Montagna G; Mathieu A; Piga M; Galeazzi M; Iuliano A; Maurel FB; Garofano AM; Perna AG; Porcasi RE
    Clin Exp Rheumatol; 2015; 33(3):375-84. PubMed ID: 26005879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Annual direct medical cost of active systemic lupus erythematosus in five European countries.
    Doria A; Amoura Z; Cervera R; Khamastha MA; Schneider M; Richter J; Guillemin F; Kobelt G; Maurel F; Garofano A; Perna A; Murray M; Schmitt C; Boucot I
    Ann Rheum Dis; 2014 Jan; 73(1):154-60. PubMed ID: 23264339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost of systemic lupus erythematosus for adult patients with active and treated disease in France (LUCIE study)].
    Amoura Z; Deligny C; Pennaforte JL; Hamidou M; Blanco P; Hachulla E; Pourrat J; Queyrel V; Garofano A; Maurel F; Levy-Bachelot L; Boucot I
    Rev Med Interne; 2014 Nov; 35(11):700-8. PubMed ID: 24630588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease.
    Khamashta MA; Bruce IN; Gordon C; Isenberg DA; Ateka-Barrutia O; Gayed M; Donatti C; Guillermin AL; Foo J; Perna A
    Lupus; 2014 Mar; 23(3):273-83. PubMed ID: 24356612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct cost of management and treatment of active systemic lupus erythematosus and its flares in Spain: the LUCIE Study.
    Cervera R; Rúa-Figueroa I; Gil-Aguado A; Sabio JM; Pallarés L; Hernández-Pastor LJ; Iglesias M
    Rev Clin Esp (Barc); 2013 Apr; 213(3):127-37. PubMed ID: 23398815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study.
    Tanaka Y; Mizukami A; Kobayashi A; Ito C; Matsuki T
    Int J Rheum Dis; 2018 Aug; 21(8):1609-1618. PubMed ID: 30146745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study.
    Zen M; Bassi N; Nalotto L; Canova M; Bettio S; Gatto M; Ghirardello A; Iaccarino L; Punzi L; Doria A
    Clin Exp Rheumatol; 2012; 30(6):856-63. PubMed ID: 22765883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [What factors determine the direct medical costs of patients with systemic lupus erythematosus in Germany? Subanalysis of the LUCIE study].
    Richter JG; Häckel B; Manger K; Riechers E; Schmeding A; Thies W; Schneider M
    Gesundheitswesen; 2014 Jan; 76(1):41-3. PubMed ID: 23512471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of systemic lupus erythematosus expression in Europe.
    Cervera R; Doria A; Amoura Z; Khamashta M; Schneider M; Guillemin F; Maurel F; Garofano A; Roset M; Perna A; Murray M; Schmitt C; Boucot I
    Autoimmun Rev; 2014 Jun; 13(6):621-9. PubMed ID: 24418306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs associated with severe and nonsevere systemic lupus erythematosus in Canada.
    Clarke AE; Urowitz MB; Monga N; Hanly JG
    Arthritis Care Res (Hoboken); 2015 Mar; 67(3):431-6. PubMed ID: 25185936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts.
    Jönsen A; Hjalte F; Willim M; Carlsson KS; Sjöwall C; Svenungsson E; Leonard D; Bengtsson C; Rantapää-Dahlqvist S; Pettersson S; Gunnarsson I; Zickert A; Gustafsson JT; Rönnblom L; Petersson IF; Bengtsson AA; Nived O
    Semin Arthritis Rheum; 2016 Jun; 45(6):684-90. PubMed ID: 26743074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and financial burden of active lupus in Greece: a nationwide study.
    Bertsias G; Karampli E; Sidiropoulos P; Gergianaki I; Drosos A; Sakkas L; Garyfallos A; Tzioufas A; Vassilopoulos D; Tsalapaki C; Sfikakis P; Panopoulos S; Athanasakis K; Perna A; Psomali D; Kyriopoulos J; Boumpas D
    Lupus; 2016 Oct; 25(12):1385-94. PubMed ID: 27055520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
    Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
    J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus.
    Yeo AL; Koelmeyer R; Kandane-Rathnayake R; Golder V; Hoi A; Huq M; Hammond E; Nab H; Nikpour M; Morand EF
    Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1289-1295. PubMed ID: 31282076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Winter lupus flares are associated with low vitamin D levels in a retrospective longitudinal study of Italian adult patients.
    Dall'Ara F; Andreoli L; Piva N; Piantoni S; Franceschini F; Tincani A
    Clin Exp Rheumatol; 2015; 33(2):153-8. PubMed ID: 25664429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic lupus erythematosus and associated healthcare resource consumption in selected cities from the Russian Federation, Republic of Kazakhstan and Ukraine: the ESSENCE study.
    Nasonov E; Soloviev S; Davidson JE; Lila A; Togizbayev G; Ivanova R; Baimukhamedov C; Omarbekova Z; Iaremenko O; Gnylorybov A; Shevchuk S; Vasylyev A; Makarova J; Tariq L
    J Med Econ; 2018 Oct; 21(10):1006-1015. PubMed ID: 29992845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study.
    McCormick N; Marra CA; Sadatsafavi M; Aviña-Zubieta JA
    Lupus; 2018 Jul; 27(8):1247-1258. PubMed ID: 29665755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.